The global Postpartum Depression Drug Market is estimated to be valued at US$ 6.638 Billion In 2022 and is expected to exhibit a CAGR of 30.25%

Postpartum Depression Drug Market

The global Postpartum Depression Drug Market is estimated to be valued at US$ 6.638 Billion In 2022 and is expected to exhibit a CAGR of 30.25% over the forecast period 2022-2029, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Postpartum depression drugs help reduce depressive symptoms such as sadness, anxiety, guilt, mood swings, trouble sleeping and lack of energy that arise after childbirth. These drugs act on neurotransmitters like serotonin and norepinephrine in the brain to alleviate symptoms. Regular intake is needed for continuous management of the condition.

Market key trends:
One of the key trends fuelling the postpartum depression drug market growth is the increasing awareness about the condition and the availability of treatment options. Several governments and non-profit organizations conduct seminars and awareness programs to educate women and their families about postpartum depression. They explain common symptoms, impact of the condition as well as safe treatment options using antidepressants. This is encouraging more women to seek medical help timely.
Here is the segment analysis and key takeaways for the given Postpartum Depression Drug market research report:

Segment Analysis
The global Postpartum Depression Drug Market is segmented based on drugs, distribution channel, and region. By drugs, the selective serotonin reuptake inhibitors (SSRIs) sub-segment dominates the market and accounted for around 65% of market share in 2021. SSRIs are commonly prescribed for postpartum depression as they are considered relatively safe and have fewer side effects compared to other antidepressants.

Key Takeaways
The global postpartum depression drug market size was valued at US$ 5.115 Billion In 2021 and is expected to witness high growth, exhibiting a CAGR of 30.25% over the forecast period from 2022-2029. The growth is attributed to increasing awareness about postpartum depression and the availability of various treatment options.

Regional analysis shows that North America dominated the global market in 2021 with a share of around 45%, followed by Europe. This is owing to early adoption of advanced drugs, stringent regulatory guidelines for marketing authorization of new drugs, and established healthcare infrastructure in the regions. However, Asia Pacific is expected to witness the highest CAGR during the forecast period due to improving healthcare facilities and growing disposable income in developing countries such as China and India.

Key players operating in the postpartum depression drug market include Sage Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Intas Pharmaceuticals Ltd., Mylan N.V., Anikem Laboratories, and Shionogi & Co., Ltd. Among them, Sage Therapeutics Inc. holds the largest market share owing to its innovative drug pipeline for treating postpartum depression.

Read More : https://www.rapidwebwire.com/postpartum-depression-drug-market-outlines-promising-growth/ 

Comments

Popular posts from this blog

Location-Based Services Market to Reach US$ 32,210 Million in 2022

Precision Medicine Market to Reach US$ 73,946.2 Million In 2022: Coherent Market Insights

The Evolution And Growth Of The Europe E-Bike Market: A Journey Towards Sustainable Mobility